Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Target ID: TTDR01153

Target Information
NameComplement C3    
Type of targetResearch target    
SynonymsC3    
DiseaseHypertension
[ICD9: 401   ICD10: I10, I11, I12, I13, I15]
[1]
PathwayComplement and coagulation cascades
Systemic lupus erythematosus
UniProt IDP01024
PDB Structure1C3D; 1GHQ; 1W2S; 2A73; 2A74; 2GOX; 2HR0; 2I07; 2ICE; 2ICF; 2NOJ; 2QKI; 2WII; 2WIN; 2WY7; 2WY8; 2XQW; 2XWB; 2XWJ; 3D5R; 3D5S; 3G6J; 3L3O; 3L5N; 3NMS; 3OED; 3OHX; 3OXU; 3RJ3; 3T4A; 4HW5; 4HWJ; 4I6O.    
FunctionC3 plays a central role in the activation of the complement system. Its processing by c3 convertase is the central reaction in both classical and alternative complement pathways. After activation c3b can bind covalently, via its reactive thiolester.    
SequenceMGPTSGPSLLLLLLTHLPLALGSPMYSIITPNILRLESEETMVLEAHDAQGDVPVTVTVH DFPGKKLVLSSEKTVLTPATNHMGNVTFTIPANREFKSEKGRNKFVTVQATFGTQVVEKV VLVSLQSGYLFIQTDKTIYTPGSTVLYRIFTVNHKLLPVGRTVMVNIENPEGIPVKQDSL SSQNQLGVLPLSWDIPELVNMGQWKIRAYYENSPQQVFSTEFEVKEYVLPSFEVIVEPTE KFYYIYNEKGLEVTITARFLYGKKVEGTAFVIFGIQDGEQRISLPESLKRIPIEDGSGEV VLSRKVLLDGVQNPRAEDLVGKSLYVSATVILHSGSDMVQAERSGIPIVTSPYQIHFTKT PKYFKPGMPFDLMVFVTNPDGSPAYRVPVAVQGEDTVQSLTQGDGVAKLSINTHPSQKPL SITVRTKKQELSEAEQATRTMQALPYSTVGNSNNYLHLSVLRTELRPGETLNVNFLLRMD RAHEAKIRYYTYLIMNKGRLLKAGRQVREPGQDLVVLPLSITTDFIPSFRLVAYYTLIGA SGQREVVADSVWVDVKDSCVGSLVVKSGQSEDRQPVPGQQMTLKIEGDHGARVVLVAVDK GVFVLNKKNKLTQSKIWDVVEKADIGCTPGSGKDYAGVFSDAGLTFTSSSGQQTAQRAEL QCPQPAARRRRSVQLTEKRMDKVGKYPKELRKCCEDGMRENPMRFSCQRRTRFISLGEAC KKVFLDCCNYITELRRQHARASHLGLARSNLDEDIIAEENIVSRSEFPESWLWNVEDLKE PPKNGISTKLMNIFLKDSITTWEILAVSMSDKKGICVADPFEVTVMQDFFIDLRLPYSVV RNEQVEIRAVLYNYRQNQELKVRVELLHNPAFCSLATTKRRHQQTVTIPPKSSLSVPYVI VPLKTGLQEVEVKAAVYHHFISDGVRKSLKVVPEGIRMNKTVAVRTLDPERLGREGVQKE DIPPADLSDQVPDTESETRILLQGTPVAQMTEDAVDAERLKHLIVTPSGCGEQNMIGMTP TVIAVHYLDETEQWEKFGLEKRQGALELIKKGYTQQLAFRQPSSAFAAFVKRAPSTWLTA YVVKVFSLAVNLIAIDSQVLCGAVKWLILEKQKPDGVFQEDAPVIHQEMIGGLRNNNEKD MALTAFVLISLQEAKDICEEQVNSLPGSITKAGDFLEANYMNLQRSYTVAIAGYALAQMG RLKGPLLNKFLTTAKDKNRWEDPGKQLYNVEATSYALLALLQLKDFDFVPPVVRWLNEQR YYGGGYGSTQATFMVFQALAQYQKDAPDHQELNLDVSLQLPSRSSKITHRIHWESASLLR SEETKENEGFTVTAEGKGQGTLSVVTMYHAKAKDQLTCNKFDLKVTIKPAPETEKRPQDA KNTMILEICTRYRGDQDATMSILDISMMTGFAPDTDDLKQLANGVDRYISKYELDKAFSD RNTLIIYLDKVSHSEDDCLAFKVHQYFNVELIQPGAVKVYAYYNLEESCTRFYHPEKEDG KLNKLCRDELCRCAEENCFIQKSDDKVTLEERLDKACEPGVDYVYKTRLVKVQLSNDFDE YIMAIEQTIKSGSDEVQVGQQRTFISPIKCREALKLEEKKHYLMWGLSSDFWGEKPNLSY IIGKDTWVEHWPEEDECQDEENQKQCQDLGAFTESMVVFGCPN
Target ValidationClick to Find Target Validation Information.    
InhibitorAc-ICV (1MeW)QDWGAHRCT-NH2[2]
Ac-ICV (1MeW)QDWGAHRCT-NH2[2]
Ac-ICV (2Nal)QDWGAHRCT-NH2[2]
Ac-ICV (5MeW)QDWGAHRCT-NH2[2]
Ac-ICV (5fW)QDWGAHRCT-NH2[2]
Ac-ICVWQD (5fW)GAHRCT-NH2[2]
Ac-ICVWQDWGAHRCT-NH2[2]
Ac-I[CV (1Nal)QDWGAHRC]T[3]
Ac-I[CV (2Igl)QDWGAHRC]T[3]
Ac-I[CV (2Igl)QDWGAHRC]T-NH2[3]
Ac-I[CV (2Nal)QDWGAHRC]T[3]
Ac-I[CV (2Nal)QDWGAHRC]T-NH2[3]
Ac-I[CV (Bpa)QDWGAHRC]T[3]
Ac-I[CV (Bpa)QDWGAHRC]T-NH2[3]
Ac-I[CV (Bta)QDWGAHRC]T[3]
Ac-I[CV (Bta)QDWGAHRC]T-NH2[3]
Ac-I[CV (Dht)QDWGAHRC]T[3]
Ac-I[CV (Yphs)QDWGAHRC]I-NH2[3]
Ac-I[CVFQDWGHHRC]T-NH2[3]
Ac-I[CVHQDWGHHRC]T-NH2[3]
Ac-I[CVSQDWGHHRC]T-NH2[3]
Ac-I[CVTQDWGHHRC]T-NH2[3]
Ac-I[CVVQDWGAHRC]T-NH2[3]
Ac-I[CVWQDWG (Abu)HRC]T-NH2[3]
Ac-I[CVWQDWGAHRC]T[3]
Ac-I[CVWQDWGAHRC]dT[3]
Ac-I[CVWQDWGHHRC]T-NH2[3]
Ac-I[CVWQDWGWHRC]T-NH2[3]
Ac-I[CVYQDWGAHRC]T-NH2[3]
S-Hydroxycysteine[4]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1Complement 3 is involved in the synthetic phenotype and exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension. 2004 Jul;44(1):42-7. Epub 2004 May 10. To Reference
Ref 2J Med Chem. 2006 Jul 27;49(15):4616-22.Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. To Reference
Ref 3J Med Chem. 2005 Jan 13;48(1):274-86.Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. To Reference
Ref 4Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543